MENLO PARK, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Reality television personality Cameran Eubanks and Dermira, Inc. (NASDAQ:DERM) announced today that they are collaborating on a new educational campaign aimed at raising awareness of hyperhidrosis, a medical condition that results in sweating beyond what is needed for normal body temperature regulation. While Eubanks is often associated with her infectious smile, an outspoken personality and sense of humor, people may not know that she has been living with hyperhidrosis for more than 25 years.

Hyperhidrosis causes people to produce 4-5 times more sweat than the average person.1 The medical condition affects approximately 15 million people in the United States2, and both men and women equally.3 Studies show that hyperhidrosis is associated with an increase in prevalence of anxiety and depression.4 People with hyperhidrosis often develop coping behaviors such as frequently changing clothes throughout the day, hiding under bulky clothing and taking multiple daily showers.4,5 These activities can often adversely impact the social and professional lives of the people who are living with the condition.

“When I started sweating excessively as a child, my mother immediately took me to see our family doctor and following the diagnosis, we faced it head on,” said Eubanks. “I feel incredibly fortunate because most people don’t have this kind of support and often feel alone. It’s important to understand that hyperhidrosis is not the result of simply being too nervous. I decided to speak out so that people are able to recognize the actual symptoms of hyperhidrosis and consider seeking treatment to help manage the condition.”  

In addition to sharing her personal story, Eubanks will also be offering advice on how she manages the condition, including her clothing choice recommendations, on the Check Your Sweat website, a new educational resource tool recently launched by Dermira. Eubanks hopes that by discussing her experience living with hyperhidrosis, others will feel inspired to speak more openly about their struggles, coping mechanisms and ultimately seek out the help of a dermatologist to learn more about the best ways to treat their excessive sweating.

“At Dermira, we are committed to identifying treatments that will ultimately serve the needs of the millions of people living with skin conditions and this starts by providing support, offering educational tools and recognizing skin conditions that may be overlooked, but have a significant impact on the lives of patients,” said Eugene Bauer, M.D., chief medical officer at Dermira. “The launch of our Check Your Sweat campaign is an opportunity to deliver on this commitment by offering people living with hyperhidrosis a chance to learn more about the condition, offer insights from experts on how to manage their excessive sweating and share information on current treatment options. We are also privileged to be working with Ms. Eubanks. We believe her openness about her hyperhidrosis will be instrumental in helping to initiate a national conversation around hyperhidrosis to increase awareness and to reduce the stigma of a condition that affects millions of people.”

The Check Your Sweat website features a sweat assessment tool that allows a person to answer a brief questionnaire and following the results, offers a discussion guide for use with a dermatologist, who can properly diagnose the condition and discuss treatment options to address excessive sweating. 

“Most people don’t realize that excessive sweating is a skin-related medical condition that can be discussed with a dermatologist,” said Adam Friedman, M.D., associate professor of dermatology at the George Washington University School of Medicine & Health Sciences. “Hyperhidrosis is a skin condition that can have a significant impact on a person’s self-esteem and many of the people I treat report feelings of helplessness and challenges navigating basic activities in their daily lives. I’m delighted that the Check Your Sweat campaign will not only educate people about hyperhidrosis, but will also help to provide coping mechanisms to manage the day-to-day challenges.”

For more information on how to manage hyperhidrosis, visit and follow @CheckYourSweat on Facebook and Instagram.

About Dermira
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s pipeline includes two late-stage product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate (formerly DRM04), for which a New Drug Application is under review by the U.S. Food and Drug Administration for the treatment of primary axillary hyperhidrosis (excessive underarm sweating beyond what is needed for normal body temperature regulation), and lebrikizumab, in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. Dermira is headquartered in Menlo Park, Calif.  For more information, please visit Follow Dermira on Twitter and LinkedIn.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (, LinkedIn page ( and corporate Twitter account (@DermiraInc) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website, LinkedIn page and Twitter account in addition to following its SEC filings, press releases, public conference calls and webcasts.

Dermira Forward-Looking Statements
The information in this news release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. This news release contains forward-looking statements that involve substantial risks and uncertainties, including statements with respect to Dermira’s ability to deliver on its commitment to identify treatments that will serve the needs of the millions of people living with skin conditions and to increase awareness of and reduce the stigma associated with hyperhidrosis. These statements deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to the design, implementation and outcomes of Dermira’s clinical trials; the outcomes of Dermira’s future meetings with regulatory agencies; Dermira’s dependence on third-party clinical research organizations, manufacturers and suppliers; Dermira’s ability to attract and retain key employees; Dermira’s ability to obtain necessary additional capital; and Dermira’s ability to continue to stay in compliance with applicable laws and regulations. You should refer to the section entitled “Risk Factors” set forth in Dermira’s Annual Report on Form 10-K, Dermira’s Quarterly Reports on Form 10-Q and other filings Dermira makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Dermira’s forward-looking statements. Furthermore, such forward-looking statements speak only as of the date of this news release. Dermira undertake no obligation to publicly update any forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.


  1. International Hyperhidrosis Society (IHHS). (2016). Defining Sweating. Accessed March 20, 2017, from
  1. Doolittle, J., Walker, P., Mills, T., & Thurston, J. (October 15, 2016). Hyperhidrosis: an update on prevalence and severity in the United States. Accessed October 04, 2017, from
  1. Haider, A., & Solish, N. (January 4, 2005). Focal hyperhidrosis: diagnosis and management. Accessed March 20, 2017, from
  1. Bahar, Rayeheh, et al. The prevalence of anxiety and depression in patients with or without hyperhidrosis (HH). Journal of the American Academy of Dermatology, vol. 75, no. 6, 2016, pp. 1126–1133., doi:10.1016/j.jaad.2016.07.001.
  1. International Hyperhidrosis Society. (2016). Diagnosing Hyperhidrosis. Accessed October 04, 2017 from


Erica Jefferson
Vice President, Corporate Communications

Ian Clements, Ph.D.
Vice President, Investor Relations

Robert H. Uhl 
Westwicke Partners
Managing Director

A video accompanying this announcement is available at

Photos accompanying this announcement are available at: